Go Pro
→ What Elon told his top shareholders in Texas (From Banyan Hill Publishing) (Ad)tc pixel Free SGMO Stock Alerts

Sangamo Therapeutics (SGMO) Financials

Sangamo Therapeutics logo
$0.07 0.00 (0.00%)
As of 08/7/2026
Compare
Annual Income Statements for Sangamo Therapeutics

Annual Income Statements for Sangamo Therapeutics

This table shows Sangamo Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -41 -72 -55 -68 -95 -121 -178 -192 -258 -98 -123
Consolidated Net Income / (Loss)		 -41 -72 -55 -69 -95 -121 -178 -192 -258 -98 -123
Net Income / (Loss) Continuing Operations		 -41 -72 -55 -69 -95 -121 -178 -192 -258 -98 -123
Total Pre-Tax Income 		-46 -72 -55 -69 -95 -121 -178 -192 -263 -98 -124
Total Operating Income		 -47 -73 -56 -77 -105 -130 -183 -201 -274 -104 -121
Total Gross Profit		 40 19 37 84 102 118 111 111 176 58 40
Total Revenue		 40 19 37 84 102 118 111 111 176 58 40
Operating Revenue		 40 19 37 84 102 118 111 111 176 58 40
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 86 92 93 162 208 248 294 313 450 162 161
Selling, General & Admin Expense		 19 26 27 47 62 67 63 63 61 45 35
Research & Development Expense		 67 66 66 115 146 181 231 250 234 112 113
Impairment Charge		 - - - - - - 0.00 0.00 155 5.52 13
Total Other Income / (Expense), net		 0.43 0.89 1.79 8.26 9.76 8.78 5.35 9.43 11 5.86 -2.26
Interest & Investment Income		 0.43 0.89 1.79 8.26 9.76 8.78 5.35 9.43 11 1.51 1.30
Other Income / (Expense), net		 - - - - - - - - - 4.35 -3.56
Income Tax Expense		 -5.72 -0.01 0.00 0.00 0.00 0.35 0.31 0.43 -5.07 -0.17 -0.57
Basic Earnings per Share		 ($0.58) ($1.02) ($0.70) ($0.70) ($0.85) ($0.90) ($1.23) ($1.25) ($1.48) ($0.49) ($0.44)
Weighted Average Basic Shares Outstanding		 69.76M 70.55M 78.08M 96.94M 112.11M 134.45M 144.57M 154.35M 174.44M 201.70M 280.19M
Diluted Earnings per Share		 ($0.58) ($1.02) ($0.70) ($0.70) ($0.85) ($0.90) ($1.23) ($1.25) ($1.48) ($0.49) ($0.44)
Weighted Average Diluted Shares Outstanding		 69.76M 70.55M 78.08M 96.94M 112.11M 134.45M 144.57M 154.35M 174.44M 201.70M 280.19M
Weighted Average Basic & Diluted Shares Outstanding		 69.76M 70.55M 78.08M 96.94M 112.11M 134.45M 145.97M 168.48M 178.91M 224.71M 414.27M

Quarterly Income Statements for Sangamo Therapeutics

This table shows Sangamo Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -104 -60 -49 -36 9.39 -22 -31 -20 -35 -37 -31
Consolidated Net Income / (Loss)		 -104 -60 -49 -36 11 -23 -31 -20 -35 -37 -31
Net Income / (Loss) Continuing Operations		 -104 -60 -49 -36 11 -23 -31 -20 -35 -37 -31
Total Pre-Tax Income 		-103 -61 -49 -36 11 -24 -30 -20 -35 -38 -31
Total Operating Income		 -106 -62 -52 -37 11 -26 -30 -18 -36 -38 -32
Total Gross Profit		 9.40 2.04 0.48 0.36 49 8.39 6.44 18 0.58 14 1.44
Total Revenue		 9.40 2.04 0.48 0.36 49 8.39 6.44 18 0.58 14 1.44
Operating Revenue		 9.40 2.04 0.48 0.36 49 - 6.44 18 0.58 14 1.44
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 116 64 52 37 39 34 36 36 36 52 33
Selling, General & Admin Expense		 14 13 12 12 11 9.87 10 9.08 7.99 7.76 6.82
Research & Development Expense		 57 51 36 24 28 24 26 27 28 31 27
Total Other Income / (Expense), net		 3.52 1.49 2.54 1.03 0.13 2.17 -0.85 -2.10 0.46 0.23 0.95
Interest & Investment Income		 3.52 1.49 0.45 0.42 0.35 2.17 0.31 0.39 0.36 0.25 0.30
Other Income / (Expense), net		 - - 2.08 0.61 -0.22 - -1.16 -2.49 0.11 -0.02 0.65
Income Tax Expense		 1.27 -0.27 0.10 0.07 0.09 -0.43 0.12 0.03 -0.16 -0.55 0.00
Basic Earnings per Share		 ($0.59) ($0.36) ($0.27) ($0.18) $0.05 ($0.09) ($0.14) ($0.08) ($0.11) ($0.11) ($0.08)
Weighted Average Basic Shares Outstanding		 177.17M 174.44M 180.34M 203.95M 208.35M 201.70M 220.27M 256.95M 304.27M 280.19M 389.62M
Diluted Earnings per Share		 ($0.59) ($0.35) ($0.27) ($0.18) $0.04 ($0.08) ($0.14) ($0.08) ($0.11) ($0.11) ($0.08)
Weighted Average Diluted Shares Outstanding		 177.17M 174.44M 180.34M 203.95M 214.33M 201.70M 220.27M 256.95M 304.27M 280.19M 389.62M
Weighted Average Basic & Diluted Shares Outstanding		 177.35M 178.91M 207.51M 208.22M 208.65M 224.71M 233.17M 301.71M 336.49M 414.27M 414.29M

Annual Cash Flow Statements for Sangamo Therapeutics

This table details how cash moves in and out of Sangamo Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 63 -47 31 90 -62 51 48 -78 -55 -3.29 -22
Net Cash From Operating Activities		 -34 -66 11 37 -144 170 -233 -224 -225 -67 -97
Net Cash From Continuing Operating Activities		 -34 -66 11 37 -143 167 -233 -224 -225 -67 -97
Net Income / (Loss) Continuing Operations		 -41 -72 -55 -69 -95 -121 -178 -192 -258 -98 -123
Consolidated Net Income / (Loss)		 -41 -72 -55 -69 -95 -121 -178 -192 -258 -98 -123
Depreciation Expense		 0.99 1.00 1.50 2.36 3.93 5.68 9.44 12 15 5.11 3.96
Amortization Expense		 0.83 0.22 -0.67 -5.83 - - 11 7.21 4.80 4.25 3.64
Non-Cash Adjustments To Reconcile Net Income		 14 15 9.18 16 19 26 26 32 183 17 22
Changes in Operating Assets and Liabilities, net		 -8.43 -11 56 93 -71 256 -102 -82 -170 4.51 -4.22
Net Cash From Investing Activities		 77 18 -77 -178 -60 -272 248 59 154 38 -0.10
Net Cash From Continuing Investing Activities		 77 18 -77 -178 -60 -272 248 59 154 38 -0.10
Purchase of Property, Plant & Equipment		 - -0.73 -3.75 -43 -21 -15 -23 -20 -21 -0.27 -0.10
Sale of Property, Plant & Equipment		 - - - - - - - - 0.00 1.95 0.00
Sale and/or Maturity of Investments		 338 237 179 392 405 315 610 357 234 36 0.00
Net Cash From Financing Activities		 20 0.34 97 232 142 153 33 85 15 28 71
Net Cash From Continuing Financing Activities		 20 0.34 97 232 142 153 33 85 15 28 71
Issuance of Common Equity		 6.80 1.11 17 16 142 154 36 87 16 29 74
Other Financing Activities, net		 13 -0.78 -0.65 0.25 -0.42 -0.77 -3.26 -2.10 -1.45 -0.90 -3.26
Effect of Exchange Rate Changes		 - - - - 0.18 -0.45 - 1.25 1.48 -2.05 4.09

Quarterly Cash Flow Statements for Sangamo Therapeutics

This table details how cash moves in and out of Sangamo Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -10 -11 8.63 -28 13 2.72 -17 13 -9.32 -9.58 6.64
Net Cash From Operating Activities		 -47 -51 -49 -27 12 -3.35 -26 -18 -28 -24 -19
Net Cash From Continuing Operating Activities		 -47 -51 -49 -27 12 -3.35 -26 -18 -28 -24 -19
Net Income / (Loss) Continuing Operations		 -104 -60 -49 -36 11 -23 -31 -20 -35 -37 -31
Consolidated Net Income / (Loss)		 -104 -60 -49 -36 11 -23 -31 -20 -35 -37 -31
Depreciation Expense		 5.49 1.83 1.41 1.24 1.22 1.24 1.02 0.99 0.99 0.96 0.72
Amortization Expense		 1.76 0.88 0.85 -1.12 3.36 0.89 0.90 0.90 0.91 0.92 0.16
Non-Cash Adjustments To Reconcile Net Income		 52 6.40 7.07 6.59 0.96 2.59 2.59 2.27 2.13 15 0.99
Changes in Operating Assets and Liabilities, net		 -2.49 0.64 -8.90 2.54 -4.45 15 -0.06 -2.34 2.41 -4.23 9.84
Net Cash From Investing Activities		 38 38 36 0.13 0.23 1.32 0.00 -0.02 -0.06 -0.01 -0.01
Net Cash From Continuing Investing Activities		 38 38 36 0.13 0.23 1.32 0.00 -0.02 -0.06 -0.01 -0.01
Purchase of Property, Plant & Equipment		 -2.74 -2.67 - - -0.12 -0.15 0.00 - -0.06 -0.01 -0.01
Net Cash From Financing Activities		 -0.10 0.17 22 -0.53 -0.20 6.99 8.13 29 19 15 27
Net Cash From Continuing Financing Activities		 -0.10 0.17 22 -0.53 -0.20 6.99 8.13 29 19 15 27
Issuance of Common Equity		 0.00 0.22 23 -0.45 - 7.21 10 29 19 15 27
Other Financing Activities, net		 -0.10 -0.05 -0.40 -0.08 -0.20 -0.22 -2.23 -0.42 -0.27 -0.35 -0.38
Effect of Exchange Rate Changes		 -0.55 1.35 -0.67 -0.26 1.13 -2.25 1.28 2.73 0.04 0.04 -0.77

Annual Balance Sheets for Sangamo Therapeutics

This table presents Sangamo Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 217 158 287 590 638 939 722 563 165 102 60
Total Current Assets		 213 150 248 411 405 660 399 300 94 52 36
Cash & Equivalents		 69 22 50 140 80 131 179 100 45 42 21
Accounts Receivable		 2.52 4.97 3.34 4.67 37 5.22 6.01 3.68 0.92 0.53 0.37
Prepaid Expenses		 0.75 1.85 1.51 5.34 5.41 12 16 18 9.26 5.18 4.37
Current Deferred & Refundable Income Taxes		 - - - - - - - - 3.14 4.07 10
Plant, Property, & Equipment, net		 2.92 6.56 31 79 30 41 52 64 27 18 11
Total Noncurrent Assets		 1.74 1.75 7.28 101 202 238 272 199 44 32 13
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - 15 13 8.94
Other Noncurrent Operating Assets		 0.15 0.17 4.68 6.86 88 86 90 81 29 19 3.94
Total Liabilities & Shareholders' Equity		 217 158 287 590 638 939 722 563 165 102 60
Total Liabilities		 25 22 99 223 205 441 347 268 82 79 74
Total Current Liabilities		 20 13 45 79 70 144 128 112 48 46 42
Accounts Payable		 8.23 6.26 11 21 6.67 13 9.76 22 15 15 14
Accrued Expenses		 - - - - 11 19 12 16 24 8.20 9.41
Current Deferred Revenue		 9.12 4.15 28 48 39 92 86 52 0.00 7.56 0.90
Current Employee Benefit Liabilities		 2.75 2.89 5.48 9.49 14 21 21 22 8.92 15 18
Total Noncurrent Liabilities		 4.70 8.41 54 145 135 298 219 156 35 33 32
Noncurrent Deferred Revenue		 4.70 4.46 29 108 81 245 167 109 0.00 5.87 5.87
Other Noncurrent Operating Liabilities		 - 3.95 25 30 47 45 45 40 35 27 26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 192 136 188 367 433 497 375 295 83 23 -14
Total Preferred & Common Equity		 192 136 188 367 433 498 375 295 83 23 -14
Preferred Stock		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 192 136 188 367 433 498 375 295 83 23 -14
Common Stock		 562 577 684 931 1,092 1,271 1,336 1,452 1,494 1,535 1,614
Retained Earnings		 -369 -441 -495 -563 -657 -778 -956 -1,149 -1,406 -1,504 -1,627
Accumulated Other Comprehensive Income / (Loss)		 - 0.02 -0.29 -1.44 -2.45 5.42 -3.99 -8.40 -4.60 -7.53 -1.46

Quarterly Balance Sheets for Sangamo Therapeutics

This table presents Sangamo Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 220 129 93 111 86 98 89 60
Total Current Assets		 148 69 40 58 38 50 44 37
Cash & Equivalents		 57 54 28 39 25 38 30 28
Accounts Receivable		 1.15 0.69 0.58 10 0.37 0.37 0.52 0.87
Prepaid Expenses		 14 13 12 8.43 7.81 6.57 8.42 3.16
Current Deferred & Refundable Income Taxes		 - - - - 4.24 4.60 4.60 5.49
Plant, Property, & Equipment, net		 28 22 21 19 17 16 15 10
Total Noncurrent Assets		 44 38 32 34 32 32 30 13
Noncurrent Deferred & Refundable Income Taxes		 - 17 14 15 13 14 14 8.76
Other Noncurrent Operating Assets		 44 21 19 19 18 17 15 3.78
Total Liabilities & Shareholders' Equity		 220 129 93 111 86 98 89 60
Total Liabilities		 85 72 69 72 81 78 82 79
Total Current Liabilities		 48 40 39 43 50 48 50 53
Accounts Payable		 15 15 18 20 18 11 16 19
Accrued Expenses		 14 18 16 12 9.80 14 9.87 15
Current Deferred Revenue		 1.49 - - 0.77 7.56 7.56 7.56 0.40
Current Employee Benefit Liabilities		 17 6.30 5.66 11 14 15 17 18
Total Noncurrent Liabilities		 36 32 30 29 32 30 32 26
Noncurrent Deferred Revenue		 0.00 - - - 5.87 5.87 5.87 5.87
Other Noncurrent Operating Liabilities		 36 32 30 29 26 24 26 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 135 57 24 39 4.91 20 6.24 -19
Total Preferred & Common Equity		 135 57 24 39 4.91 20 6.24 -19
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 135 57 24 39 4.91 20 6.24 -19
Common Stock		 1,488 1,518 1,521 1,524 1,545 1,576 1,598 1,642
Retained Earnings		 -1,346 -1,455 -1,492 -1,481 -1,535 -1,555 -1,590 -1,658
Accumulated Other Comprehensive Income / (Loss)		 -6.58 -5.80 -5.88 -4.22 -5.53 -1.46 -1.45 -2.51

Annual Metrics And Ratios for Sangamo Therapeutics

This table displays calculated financial ratios and metrics derived from Sangamo Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 70,046,841.00 70,623,858.00 84,520,951.00 102,092,863.00 115,937,618.00 141,441,378.00 145,674,591.00 163,880,007.00 177,346,980.00 - 336,494,489.00
DEI Adjusted Shares Outstanding		 70,046,841.00 70,623,858.00 84,520,951.00 102,092,863.00 115,937,618.00 141,441,378.00 145,674,591.00 163,880,007.00 177,346,980.00 - 336,494,489.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.58 -1.01 -0.65 -0.67 -0.82 -0.86 -1.22 -1.17 -1.45 - -0.37
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -13.80% -50.96% 88.60% 130.95% 21.29% 15.39% -6.34% 0.54% 58.34% -67.20% -31.57%
EBITDA Growth		 -81.84% -58.39% 22.15% -45.17% -25.59% -22.34% -31.47% -11.73% -39.67% 62.67% -29.85%
EBIT Growth		 -77.37% -54.86% 22.32% -36.89% -36.33% -23.17% -41.52% -9.79% -36.13% 62.06% -25.28%
NOPAT Growth		 -74.96% -54.86% 22.32% -36.89% -36.33% -23.17% -41.52% -9.79% -36.13% 62.06% -16.61%
Net Income Growth		 -54.08% -76.05% 23.85% -26.24% -38.51% -26.94% -47.20% -7.84% -34.09% 62.01% -25.52%
EPS Growth		 -48.72% -75.86% 31.37% 0.00% -21.43% -5.88% -36.67% -1.63% -18.40% 66.89% 10.20%
Operating Cash Flow Growth		 -494.19% -95.38% 116.97% 226.95% -495.08% 217.64% -237.31% 4.13% -0.54% 70.14% -44.79%
Free Cash Flow Firm Growth		 -305.07% -68.79% 117.42% -829.72% -99.79% 198.32% -253.31% 6.76% 5.30% 74.91% -32.96%
Invested Capital Growth		 16.82% 61.72% -789.91% 41.73% 247.32% -501.77% 54.07% 85.99% 115.06% -1,115.81% -83.91%
Revenue Q/Q Growth		 -12.85% -1.02% 12.82% 19.46% 37.65% -19.73% 2.01% -0.67% -12.51% 12.33% 20.31%
EBITDA Q/Q Growth		 -33.17% 7.86% -8.74% -11.33% 21.81% -55.88% 8.77% -4.42% -3.45% 27.22% -15.84%
EBIT Q/Q Growth		 -31.43% 7.45% -7.51% -9.99% 17.45% -53.04% 1.89% -8.34% -2.49% 25.76% -14.47%
NOPAT Q/Q Growth		 -31.43% 7.45% -7.51% -9.99% 17.45% -53.04% 1.89% -8.34% -2.49% 25.76% -11.20%
Net Income Q/Q Growth		 -31.26% 5.77% -6.78% -9.76% 19.91% -56.29% 0.91% -8.14% -3.34% 27.37% -12.88%
EPS Q/Q Growth		 -31.82% 5.56% -1.45% -2.94% 21.30% 0.00% 0.00% -5.93% -2.07% 35.53% -7.32%
Operating Cash Flow Q/Q Growth		 -23.39% -4.21% -31.22% -38.95% 11.81% 10.77% -26.20% -1.98% 2.81% 41.27% -27.64%
Free Cash Flow Firm Q/Q Growth		 -17.21% -2.71% -42.33% -110.65% 12.74% 22.71% -21.97% -7.82% 10.76% 45.62% -32.05%
Invested Capital Q/Q Growth		 -5.01% 43.65% 15.00% 58.21% 399.98% -12.02% 20.93% 69.55% -32.94% -28,479.10% -45.01%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -113.92% -367.95% -151.87% -95.46% -98.85% -104.80% -147.11% -163.49% -144.21% -164.15% -296.32%
Operating Margin		 -118.51% -374.23% -154.13% -91.35% -102.69% -109.61% -165.61% -180.85% -155.48% -179.88% -306.53%
EBIT Margin		 -118.51% -374.23% -154.13% -91.35% -102.69% -109.61% -165.61% -180.85% -155.48% -179.88% -315.54%
Profit (Net Income) Margin		 -102.94% -369.58% -149.23% -81.57% -93.16% -102.48% -161.06% -172.76% -146.30% -169.45% -310.81%
Tax Burden Percent		 87.67% 99.98% 100.00% 100.00% 100.00% 100.29% 100.17% 100.22% 98.07% 99.83% 99.54%
Interest Burden Percent		 99.08% 98.78% 96.82% 89.29% 90.72% 93.23% 97.08% 95.31% 95.95% 94.36% 98.96%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -946.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -940.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 922.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -20.40% -43.61% -33.67% -24.82% -23.85% -26.04% -40.86% -57.37% -136.47% -185.39% -2,891.84%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -319.90% 0.00% 0.00% 0.00% -10,939.39% 0.00% 0.00%
Operating Return on Assets (OROA)		 -20.35% -38.69% -25.35% -17.59% -17.13% -16.44% -22.08% -31.34% -75.29% -77.89% -154.67%
Return on Assets (ROA)		 -17.68% -38.20% -24.55% -15.71% -15.54% -15.37% -21.48% -29.94% -70.85% -73.38% -152.35%
Return on Common Equity (ROCE)		 -20.40% -43.61% -33.67% -24.78% -23.83% -26.06% -40.90% -57.37% -136.47% -185.39% -2,891.84%
Return on Equity Simple (ROE_SIMPLE)		 -21.15% -52.61% -29.04% -18.80% -22.06% -24.31% -47.50% -65.19% -311.06% -430.13% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -51 -39 -54 -74 -91 -128 -141 -192 -73 -85
NOPAT Margin		 -82.95% -261.96% -107.89% -63.95% -71.88% -76.73% -115.93% -126.59% -108.84% -125.91% -214.57%
Net Nonoperating Expense Percent (NNEP)		 -3.63% -11.87% -7.81% -4.62% -5.56% -5.66% -8.64% -13.31% -33.99% -40.94% -121.10%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -231.40% -319.62% 594.81%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 48.55% 135.80% 74.38% 55.34% 60.22% 56.77% 57.11% 56.32% 34.71% 77.38% 88.20%
R&D to Revenue		 169.95% 338.43% 179.75% 136.01% 142.46% 152.84% 208.51% 224.53% 132.81% 192.94% 284.87%
Operating Expenses to Revenue		 218.51% 474.23% 254.13% 191.35% 202.69% 209.61% 265.61% 280.85% 255.48% 279.88% 406.53%
Earnings before Interest and Taxes (EBIT)		 -47 -73 -56 -77 -105 -130 -183 -201 -274 -104 -125
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -71 -56 -81 -101 -124 -163 -182 -254 -95 -117
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.32 1.58 7.38 3.20 2.24 4.43 2.91 1.74 1.16 9.35 0.00
Price to Tangible Book Value (P/TBV)		 3.35 1.60 7.44 4.31 2.85 5.56 3.88 2.49 1.16 9.35 0.00
Price to Revenue (P/Rev)		 16.17 11.11 37.91 13.88 9.47 18.67 9.87 4.62 0.55 3.68 3.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 12.10 0.00 0.00 0.00 8.14 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 10.89 3.76 31.23 9.15 5.72 12.81 5.67 1.86 0.09 2.96 3.04
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 102.14 21.14 0.00 8.91 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 107.44 0.00 0.00 9.94 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.09 -1.07 -1.19 -1.16 -0.98 -1.16 -1.33 -1.15 -1.03 -1.16 -7.39
Leverage Ratio		 1.15 1.14 1.37 1.58 1.53 1.69 1.90 1.92 1.93 2.53 18.98
Compound Leverage Factor		 1.14 1.13 1.33 1.41 1.39 1.58 1.85 1.83 1.85 2.38 18.78
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.20% 0.04% -0.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 99.80% 99.96% 100.17% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 13.63 1.69 6.33 2.20 1.65 2.17 -0.20 -2.29 -15.27 -21.84 -43.35
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.13% 0.12% -0.07% -0.10% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 10.58 11.25 5.54 5.23 5.80 4.60 3.12 2.69 1.98 1.13 0.84
Quick Ratio		 10.54 11.12 5.50 5.16 5.73 4.51 2.99 2.53 1.72 0.93 0.50
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -36 -61 11 -78 -155 152 -234 -218 -206 -52 -69
Operating Cash Flow to CapEx		 0.00% -9,000.41% 298.03% 84.87% -698.44% 1,154.51% -1,002.02% -1,108.66% -1,062.83% 0.00% -95,301.96%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.17 0.10 0.16 0.19 0.17 0.15 0.13 0.17 0.48 0.43 0.49
Accounts Receivable Turnover		 6.14 5.18 8.80 21.07 4.93 5.61 19.70 22.97 76.61 79.78 88.19
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 17.99 4.09 1.94 1.54 1.89 3.32 2.38 1.93 3.90 2.58 2.73
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 59.49 70.53 41.50 17.32 74.09 65.06 18.53 15.89 4.76 4.58 4.14
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 59.49 70.53 41.50 17.32 74.09 65.06 18.53 15.89 4.76 4.58 4.14
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -17 -6.34 -56 -33 48 -195 -89 -13 1.89 -19 -35
Invested Capital Turnover		 -2.17 -1.69 -1.17 -1.89 13.17 -1.62 -0.78 -2.18 -33.15 -6.70 -1.46
Increase / (Decrease) in Invested Capital		 3.35 10 -50 24 81 -243 105 77 14 -21 -16
Enterprise Value (EV)		 431 73 1,142 773 586 1,514 628 207 15 171 120
Market Capitalization		 640 215 1,386 1,172 970 2,207 1,093 515 96 213 141
Book Value per Share		 $2.75 $1.93 $2.22 $3.59 $3.73 $3.52 $2.58 $1.80 $0.47 $0.11 ($0.04)
Tangible Book Value per Share		 $2.72 $1.91 $2.20 $2.67 $2.93 $2.81 $1.94 $1.26 $0.47 $0.11 ($0.04)
Total Capital		 192 136 188 367 433 497 375 295 83 23 -14
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -209 -143 -244 -400 -384 -692 -465 -307 -81 -42 -21
Capital Expenditures (CapEx)		 0.00 0.73 3.75 43 21 15 23 20 21 -1.68 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -17 -6.25 -40 -68 -27 -125 -106 -89 -34 -36 -28
Debt-free Net Working Capital (DFNWC)		 192 136 204 332 336 516 271 189 47 5.89 -6.64
Net Working Capital (NWC)		 192 136 204 332 336 516 271 189 47 5.89 -6.64
Net Nonoperating Expense (NNE)		 7.90 21 15 15 22 30 50 51 66 25 38
Net Nonoperating Obligations (NNO)		 -209 -143 -244 -400 -384 -692 -465 -307 -81 -42 -21
Total Depreciation and Amortization (D&A)		 1.82 1.22 0.83 -3.47 3.93 5.68 20 19 20 9.09 7.60
Debt-free, Cash-free Net Working Capital to Revenue		 -41.77% -32.21% -108.76% -80.66% -26.24% -106.02% -95.45% -79.98% -19.52% -62.34% -69.74%
Debt-free Net Working Capital to Revenue		 486.82% 702.92% 556.62% 393.13% 327.65% 436.68% 244.70% 169.47% 26.44% 10.18% -16.78%
Net Working Capital to Revenue		 486.82% 702.92% 556.62% 393.13% 327.65% 436.68% 244.70% 169.47% 26.44% 10.18% -16.78%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.58) ($1.02) ($0.70) ($0.70) ($0.85) ($0.90) ($1.23) ($1.25) ($1.48) ($0.49) ($0.44)
Adjusted Weighted Average Basic Shares Outstanding		 70.37M 70.88M 86.34M 102.27M 116.02M 143.25M 144.57M 154.35M 174.44M 201.70M 280.19M
Adjusted Diluted Earnings per Share		 ($0.58) ($1.02) ($0.70) ($0.70) ($0.85) ($0.90) ($1.23) ($1.25) ($1.48) ($0.49) ($0.44)
Adjusted Weighted Average Diluted Shares Outstanding		 70.37M 70.88M 86.34M 102.27M 116.02M 143.25M 144.57M 154.35M 174.44M 201.70M 280.19M
Adjusted Basic & Diluted Earnings per Share		 ($0.58) ($1.02) ($0.70) ($0.70) ($0.85) ($0.90) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 69.76M 70.55M 78.08M 96.94M 112.11M 134.45M 145.97M 168.48M 178.91M 224.71M 414.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -51 -39 -54 -74 -91 -128 -141 -83 -69 -76
Normalized NOPAT Margin		 -82.95% -261.96% -107.89% -63.95% -71.88% -76.73% -115.93% -126.59% -47.26% -119.23% -191.15%
Pre Tax Income Margin		 -117.42% -369.65% -149.23% -81.57% -93.16% -102.19% -160.79% -172.37% -149.18% -169.74% -312.25%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Sangamo Therapeutics

This table displays calculated financial ratios and metrics derived from Sangamo Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 177,111,718.00 177,346,980.00 178,906,350.00 207,510,076.00 208,220,670.00 - 224,710,019.00 233,166,972.00 301,709,485.00 336,494,489.00 414,274,017.00
DEI Adjusted Shares Outstanding		 177,111,718.00 177,346,980.00 178,906,350.00 207,510,076.00 208,220,670.00 - 224,710,019.00 233,166,972.00 301,709,485.00 336,494,489.00 414,274,017.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.59 -0.34 -0.27 -0.17 0.05 - -0.14 -0.09 -0.12 -0.11 -0.07
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -64.48% -92.50% -99.70% -94.79% 425.77% 310.77% 1,238.25% 5,042.13% -98.82% 88.43% -77.60%
EBITDA Growth		 -97.35% -16.67% -309.11% 69.25% 115.12% 59.80% 38.84% 49.25% -323.83% -67.39% -5.39%
EBIT Growth		 -93.84% -12.04% -374.16% 70.49% 109.78% 58.12% 37.73% 44.21% -440.50% -58.48% -1.65%
NOPAT Growth		 -93.84% -12.04% -301.84% 69.99% 114.16% 58.12% 42.50% 51.85% -336.03% -46.99% -7.82%
Net Income Growth		 -95.96% -16.01% -332.29% 68.45% 110.25% 61.20% 37.67% 44.68% -427.31% -59.94% -1.30%
EPS Growth		 -73.53% -9.38% -325.00% 72.73% 106.78% 77.14% 48.15% 55.56% -375.00% -37.50% 42.86%
Operating Cash Flow Growth		 11.80% 11.41% 26.60% 55.72% 124.86% 93.37% 46.27% 32.46% -342.35% -628.23% 26.26%
Free Cash Flow Firm Growth		 -7.31% 49.97% 140.12% 116.16% 111.34% 104.91% -98.43% -92.76% -104.99% -475.85% 334.64%
Invested Capital Growth		 106.84% 115.06% -98.56% -107.95% -102.38% -1,115.81% -1,586.36% -357.57% -36,146.27% -83.91% -129.56%
Revenue Q/Q Growth		 37.50% -78.27% -76.44% -25.99% 13,779.78% -83.02% -14.75% 184.39% -96.83% 2,348.88% -89.87%
EBITDA Q/Q Growth		 16.12% 40.15% 20.49% 22.97% 141.23% -286.98% -32.94% 36.08% -81.85% -8.33% 16.30%
EBIT Q/Q Growth		 13.89% 41.68% 20.33% 26.24% 128.54% -344.47% -27.65% 33.92% -74.22% -7.84% 18.13%
NOPAT Q/Q Growth		 13.89% 41.68% 16.97% 28.03% 140.62% -272.54% -14.00% 39.74% -99.12% -7.45% 16.38%
Net Income Q/Q Growth		 9.03% 42.11% 18.59% 26.40% 129.54% -319.23% -30.78% 34.68% -74.77% -7.13% 17.17%
EPS Q/Q Growth		 10.61% 40.68% 22.86% 33.33% 122.22% -300.00% -75.00% 42.86% -37.50% 0.00% 27.27%
Operating Cash Flow Q/Q Growth		 22.10% -6.86% 3.71% 44.75% 143.74% -128.50% -680.33% 30.56% -56.94% 14.37% 20.99%
Free Cash Flow Firm Q/Q Growth		 35.44% 51.15% 198.85% -48.16% -54.72% -78.84% -68.37% 139.04% -131.16% -1,495.29% 136.58%
Invested Capital Q/Q Growth		 -94.54% -32.94% -27.64% -400.29% 98.36% -28,479.10% -5.88% 7.56% -29.58% -45.01% -32.16%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,055.05% -2,906.37% -9,810.60% -10,210.11% 30.33% -284.39% -448.39% -100.78% -5,774.18% -255.42% -2,109.43%
Operating Margin		 -1,132.24% -3,039.13% -10,712.27% -10,416.85% 21.52% -309.85% -460.28% -97.54% -6,119.28% -268.51% -2,215.40%
EBIT Margin		 -1,132.24% -3,039.13% -10,279.00% -10,244.38% 21.07% -309.85% -478.28% -111.14% -6,100.86% -268.65% -2,170.25%
Profit (Net Income) Margin		 -1,108.35% -2,952.74% -10,205.61% -10,148.31% 21.60% -278.92% -475.33% -109.18% -6,012.05% -263.00% -2,149.45%
Tax Burden Percent		 101.23% 99.55% 100.20% 100.21% 99.18% 98.21% 100.39% 100.14% 99.54% 98.54% 100.00%
Interest Burden Percent		 96.70% 97.60% 99.09% 98.86% 103.36% 91.66% 99.00% 98.10% 99.00% 99.34% 99.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -2,930.77% -3,776.64% 813.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -2,921.99% -3,766.95% 813.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 2,207.13% 3,072.97% -800.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -112.37% -136.47% -723.65% -703.67% 12.97% -185.39% -257.94% -292.47% -480.02% -2,891.84% 1,755.71%
Cash Return on Invested Capital (CROIC)		 -8,219.91% -10,939.39% -306.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -560.60% -1,471.75% -677.03% -601.65% 6.66% -134.17% -283.49% -95.30% -2,006.60% -131.69% -1,026.44%
Return on Assets (ROA)		 -548.78% -1,429.92% -672.19% -596.00% 6.82% -120.78% -281.74% -93.62% -1,977.39% -128.91% -1,016.60%
Return on Common Equity (ROCE)		 -112.37% -136.47% -723.65% -703.67% 12.97% -185.39% -257.94% -292.47% -480.02% -2,891.84% 1,755.71%
Return on Equity Simple (ROE_SIMPLE)		 -184.93% 0.00% -578.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -74 -43 -36 -26 11 -18 -21 -12 -25 -27 -22
NOPAT Margin		 -792.57% -2,127.39% -7,498.59% -7,291.80% 21.34% -216.89% -322.19% -68.28% -4,283.49% -187.95% -1,550.78%
Net Nonoperating Expense Percent (NNEP)		 -12.30% -8.68% -8.79% -9.69% 0.15% -8.47% -24.49% -22.64% -28.81% -33.97% -32.72%
Return On Investment Capital (ROIC_SIMPLE)		 - -52.41% -63.62% -109.58% 26.94% -79.90% -422.74% -63.76% -398.64% 187.43% 117.98%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 148.10% 641.48% 2,446.36% 3,383.43% 22.36% 117.62% 156.27% 49.58% 1,375.56% 54.53% 472.82%
R&D to Revenue		 607.46% 2,483.15% 7,461.75% 6,804.21% 56.12% 282.25% 404.01% 147.95% 4,843.72% 220.96% 1,842.58%
Operating Expenses to Revenue		 1,232.24% 3,139.13% 10,812.27% 10,516.85% 78.49% 399.87% 560.28% 197.54% 6,219.28% 368.51% 2,315.40%
Earnings before Interest and Taxes (EBIT)		 -106 -62 -49 -36 10 -26 -31 -20 -35 -38 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -99 -59 -47 -36 15 -24 -29 -18 -34 -36 -30
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.79 1.16 2.11 3.14 4.61 9.35 30.04 6.44 32.54 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.79 1.16 2.11 3.14 4.61 9.35 30.04 6.44 32.54 0.00 0.00
Price to Revenue (P/Rev)		 0.53 0.55 6.39 6.06 3.45 3.68 2.31 1.54 6.18 3.57 2.96
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 8.14 47.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.09 3.44 3.79 2.70 2.96 1.92 1.08 5.25 3.04 2.16
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.09 -1.03 -0.76 -0.82 -0.98 -1.16 -1.31 -1.53 -1.54 -7.39 3.76
Leverage Ratio		 1.83 1.93 1.45 1.62 1.90 2.53 3.49 4.40 4.41 18.98 -10.40
Compound Leverage Factor		 1.77 1.88 1.44 1.61 1.97 2.32 3.46 4.32 4.36 18.86 -10.30
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -7.97 -11.04 -15.66 -22.96 -16.19 -19.31 -24.46 -21.17 -24.66 -38.57 -39.40
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.04 1.98 1.71 1.03 1.35 1.13 0.76 1.05 0.88 0.84 0.70
Quick Ratio		 2.76 1.72 1.37 0.73 1.15 0.93 0.52 0.81 0.60 0.50 0.54
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -118 -58 57 30 13 2.84 0.90 2.15 -0.67 -11 3.90
Operating Cash Flow to CapEx		 -1,723.51% -1,892.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -44,528.13% -174,307.14% -148,323.08%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.50 0.48 0.07 0.06 0.32 0.43 0.59 0.86 0.33 0.49 0.47
Accounts Receivable Turnover		 71.05 76.61 4.86 7.45 8.98 79.78 120.64 171.47 5.97 88.19 55.78
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.77 3.90 0.46 0.30 2.20 2.58 3.28 4.50 1.94 2.73 2.54
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 5.14 4.76 75.09 49.01 40.64 4.58 3.03 2.13 61.17 4.14 6.54
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 5.14 4.76 75.09 49.01 40.64 4.58 3.03 2.13 61.17 4.14 6.54
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.81 1.89 1.36 -4.10 -0.07 -19 -20 -19 -24 -35 -47
Invested Capital Turnover		 -10.52 -33.15 0.39 0.52 38.11 -6.70 -6.74 -7.16 -2.70 -1.46 -1.03
Increase / (Decrease) in Invested Capital		 44 14 -93 -56 -2.88 -21 -22 -15 -24 -16 -26
Enterprise Value (EV)		 -26 15 65 47 141 171 122 88 173 120 75
Market Capitalization		 106 96 120 74 180 213 147 126 203 141 102
Book Value per Share		 $0.76 $0.47 $0.32 $0.11 $0.19 $0.11 $0.02 $0.08 $0.02 ($0.04) ($0.05)
Tangible Book Value per Share		 $0.76 $0.47 $0.32 $0.11 $0.19 $0.11 $0.02 $0.08 $0.02 ($0.04) ($0.05)
Total Capital		 135 83 57 24 39 23 4.91 20 6.24 -14 -19
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -132 -81 -55 -28 -39 -42 -25 -38 -31 -21 -28
Capital Expenditures (CapEx)		 2.74 2.67 0.00 0.00 -0.23 -1.32 0.00 0.00 0.06 0.01 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -33 -34 -27 -27 -24 -36 -37 -36 -37 -28 -44
Debt-free Net Working Capital (DFNWC)		 99 47 28 1.07 15 5.89 -12 2.23 -6.05 -6.64 -16
Net Working Capital (NWC)		 99 47 28 1.07 15 5.89 -12 2.23 -6.05 -6.64 -16
Net Nonoperating Expense (NNE)		 30 17 13 10 -0.13 5.20 9.86 7.49 10 11 8.63
Net Nonoperating Obligations (NNO)		 -132 -81 -55 -28 -39 -42 -25 -38 -31 -21 -28
Total Depreciation and Amortization (D&A)		 7.25 2.71 2.25 0.12 4.58 2.14 1.92 1.90 1.90 1.88 0.88
Debt-free, Cash-free Net Working Capital to Revenue		 -16.39% -19.52% -143.63% -217.61% -46.34% -62.34% -58.26% -44.20% -111.26% -69.74% -126.19%
Debt-free Net Working Capital to Revenue		 49.20% 26.44% 151.39% 8.72% 28.63% 10.18% -18.77% 2.73% -18.40% -16.78% -46.36%
Net Working Capital to Revenue		 49.20% 26.44% 151.39% 8.72% 28.63% 10.18% -18.77% 2.73% -18.40% -16.78% -46.36%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.59) ($0.36) ($0.27) ($0.18) $0.05 ($0.09) ($0.14) ($0.08) ($0.11) ($0.11) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 177.17M 174.44M 180.34M 203.95M 208.35M 201.70M 220.27M 256.95M 304.27M 280.19M 389.62M
Adjusted Diluted Earnings per Share		 ($0.59) ($0.35) ($0.27) ($0.18) $0.04 ($0.08) ($0.14) ($0.08) ($0.11) ($0.11) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 177.17M 174.44M 180.34M 203.95M 214.33M 201.70M 220.27M 256.95M 304.27M 280.19M 389.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 177.35M 178.91M 207.51M 208.22M 208.65M 224.71M 233.17M 301.71M 336.49M 414.27M 414.29M
Normalized Net Operating Profit after Tax (NOPAT)		 -43 -43 -33 -25 11 -18 -21 -12 -25 -17 -22
Normalized NOPAT Margin		 -458.89% -2,117.24% -6,865.68% -7,061.35% 21.34% -216.89% -322.19% -68.28% -4,283.49% -122.84% -1,550.78%
Pre Tax Income Margin		 -1,094.84% -2,966.06% -10,185.24% -10,127.53% 21.78% -284.01% -473.48% -109.03% -6,039.76% -266.88% -2,149.45%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Sangamo Therapeutics (NASDAQ: SGMOQ) is still operating in a highly challenged financial position, but the latest quarter shows a meaningful improvement in revenue and cash burn compared with the prior year. For Q1 2026, revenue rose to $1.4 million from $581,000 in Q3 2025 and $356,000 in Q2 2025, while operating loss narrowed to $31.9 million from $35.6 million in the prior quarter. The company remains unprofitable and dependent on financing, but it has improved liquidity since year-end 2025.

  • Q1 2026 revenue increased to $1.44 million, up sharply from $0.58 million in Q3 2025 and $0.36 million in Q2 2025.
  • Operating loss improved to $31.9 million in Q1 2026 from $35.6 million in Q3 2025 and $38.2 million in Q4 2025.
  • Net loss also improved to $31.0 million, compared with $37.4 million in Q4 2025.
  • Cash and equivalents rose to $27.6 million at March 31, 2026, from $15.7 million at year-end 2025.
  • The company generated $27.1 million from common equity issuance in Q1 2026, extending liquidity.
  • Quarterly operating cash outflow improved to -$19.3 million in Q1 2026 from -$24.4 million in Q4 2025.
  • Research and development spending remained high at $26.6 million, showing continued investment in the pipeline.
  • Selling, general and administrative expense declined to $6.8 million from $7.8 million in Q4 2025.
  • Sangamo remains deeply unprofitable, with a quarterly net loss of $31.0 million versus only $1.4 million in revenue.
  • Total liabilities were $78.9 million, which exceed total assets of $60.0 million, leaving shareholders’ equity at negative $19.0 million.

Over the longer four-year period, the trend is mixed. Revenue has been volatile and generally very low outside a few quarters, while losses have remained substantial. The company’s cash position has improved from the severe year-end 2025 low, but it continues to rely on equity financing to fund operations. Share dilution has also been significant, with weighted average basic shares rising to 389.6 million in Q1 2026 from 220.3 million in Q1 2025.

Bottom line: The latest quarter shows some operational improvement and better liquidity, but Sangamo Therapeutics still faces major balance-sheet and profitability risks. Investors should view the stock as a speculative biotech name that likely needs continued financing or a major business catalyst to support a sustainable turnaround.

08/08/26 02:58 PM ETAI Generated. May Contain Errors.

Sangamo Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sangamo Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Sangamo Therapeutics' net income appears to be on an upward trend, with a most recent value of -$122.93 million in 2025, rising from -$40.70 million in 2015. The previous period was -$97.94 million in 2024. See where experts think Sangamo Therapeutics is headed by visiting Sangamo Therapeutics' forecast page.

Sangamo Therapeutics' total operating income in 2025 was -$121.24 million, based on the following breakdown:
  • Total Gross Profit: $39.55 million
  • Total Operating Expenses: $160.79 million

Over the last 10 years, Sangamo Therapeutics' total revenue changed from $39.54 million in 2015 to $39.55 million in 2025, a change of 0.0%.

Sangamo Therapeutics' total liabilities were at $74.01 million at the end of 2025, a 6.2% decrease from 2024, and a 198.5% increase since 2015.

In the past 10 years, Sangamo Therapeutics' cash and equivalents has ranged from $20.95 million in 2025 to $178.87 million in 2021, and is currently $20.95 million as of their latest financial filing in 2025.

Over the last 10 years, Sangamo Therapeutics' book value per share changed from 2.75 in 2015 to -0.04 in 2025, a change of -101.5%.


Related Companies

Financial statements for NASDAQ:SGMO last updated on 7/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX Earnings Crash: The End of the AI Bubble?
Jeremy Grantham calls today's market the biggest investment bubble in American history, and Ray Dalio agrees. ...
TradeSmith | Sponsoredtc pixel
Washington just doubled the size of this company
On May 21, 2026, a federal bank's board voted unanimously to approve nearly $3 billion in financing for a smal...
Behind the Markets | Sponsoredtc pixel
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...
Freedom Financial | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Socialists Just Took Over America’s Biggest City. This 41-Year Wall Street Veteran Says They’re About to Get Blindsided.
A 41-year Wall Street veteran who recommended Apple at $1, NVIDIA at $1.10, and Amazon at $1.77 says America's...
The Oxford Club | Sponsoredtc pixel
Why the Fed Cant Actually Raise Rates on 9-6 Trillion in Debt
Kevin Warsh's hint that the Fed will not hesitate to act sent a shock through gold markets, even though rates ...
Golden Portfolio | Sponsoredtc pixel